trial fibrillation (AF) is a common postoperative complication after coronary artery bypass grafting (CABG), with a prevalence of 30-45%. [1] [2] [3] [4] Because of impaired atrial pump function and ventricular filling, AF following CABG may decrease cardiac output, hence causing unstable hemodynamics, prolonging the need for assisted ventilation and inotropic support, significant morbidity, and increased length of hospital stay and costs. 1, 2 Therefore, it becomes crucial for clinicians to prevent AF following CABG.
The causes and pathogenesis of AF following CABG are multifactorial andmay be related to surgical technical factors and a multitude of clinical factors; previous studies confirm that the inflammatory response plays an important role in the development of AF following CABG. 5, 6 Statins, independent of their cholesterol-lowering property, are reported to reduce the risk of AF through their pleiotropic effects, such as antiinflammatory, and antioxidant properties, modification of extracellular matrix remodeling and indirect antiarrhythmic effects by autonomic modulation or direct antiarrhythmic effects through stabilization of transmembrane ion channel properties. [5] [6] [7] Recent clinical studies report that preoperative statin treatment significantly decreases the incidence of AF following CABG with cardiopulmonary bypass. 3, [7] [8] [9] [10] However, there are only a few reports on statins preventing AF following CABG without cardiopulmonary bypass (off-pump CABG (OPCABG)). Song et al report that pretreatment with atorvastatin significantly reduced the occurrence of AF following OPCABG, 11 but as their study was not a double-blind and placebo-controlled trial, definitive conclusions cannot be drawn. In addition, AF has significant genetic heterogeneity, 12 and the effects of statins have ethnic differences, 13 so it is necessary to evaluate the effects of statins on postoperative AF in domestic patients undergoing OPCABG.
In this study, we evaluated whether administration of atorvastatin 20 mg/day, started 1 week before the scheduled surgery, prevented AF following selective OPCABG vs placebo in a randomized, double-blind, placebo-controlled trial over a 2-year period. Exclusion criteria were as follows: adverse reactions of the digestive system or continuous elevated liver enzymes, peri-operative unstable hemodynamics, peri-operative intraaortic balloon pump (IABP) requirement, and postoperative important organ dysfunction or failure.
Methods

Patients
All selected patients had preoperative ECG, chest X-ray, echocardiography and coronary artery angiography. All operations were completed by the same surgeon.
This study protocol was approved by the medical ethics committee and was consistent with the spirit of the Declaration of Helsinki. All selected patients signed an informed consent approved by the ethics committee.
Definition of Postoperative AF
After OPCABG, any episode of AF that was registered by the monitoring system on a rhythm strip or the 12-lead ECG and lasting for more than 5 min with or without symptoms, was defined as postoperative AF.
Randomization and Therapy
All selected patients were randomly divided into a statin group and a control group through a computer-generated randomization sequence. The randomization assignment for each patient was kept in a sealed envelope, which was opened by a trial investigator at the time of patient enrollment. The assigned therapy was fully blinded: surgeons and investigators performing postoperative assessments were unaware of the randomization assignment. Patients in the statin group were administered oral atorvastatin (Pfizer Pharmaceutical Co Ltd, New York, NY, USA) 20 mg/day beginning 7 days before the scheduled surgery. Patients in the control group were administered a placebo beginning at the same time. All selected patients had continuous ECG monitoring for at least 7 days following OPCABG and subsequently they had daily 12-lead ECG monitoring until hospital discharge. The occurrence and duration of postoperative AF, postoperative time of AF occurrence and the highest ventricular rate were recorded, as were postoperative complications, mortality and adverse responses to atorvastatin.
At the onset of postoperative AF, patients received a single loading dose (5 mg/kg, maximum 300 mg) of intravenous amiodarone bolus over 30 min and thereafter received a continuous amiodarone infusion at a rate of 0.5 mg · kg -1 · h -1 . If normal sinus rhythm was established within 24 h, the intravenous infusion was continued for another 24 h with concomitant oral amiodarone overlap (400 mg amiodarone orally twice daily for 5 days followed by 200 mg amiodarone orally once daily for 7 days). If normal sinus rhythm was not established within 24 h of medical treatment, then external electrical cardioversion was performed. After 48 h, the intravenous infusion was discontinued and the oral regimen maintained.
The primary endpoint of the trial was the occurrence of postoperative AF. The secondary endpoints were major adverse cardiac and cerebrovascular events (death, stroke, myocardial infarction (MI) or need for coronary revascularization) from the time of operation until hospital discharge, persistent postoperative in-hospital AF and identification of variables that predict postoperative AF.
C-reactive protein (CRP) levels were assessed in all selected patients before surgery and every 24 h postoperatively until discharge from hospital. CRP was measured by the KRIPTOR ultrasensitive immunofluorescent assay (Brahms, Hennigsdorf/Berlin, Germany) with a detection limit of 0.06 mg/L. 
Statistical Analysis
Statistical analysis was performed using the SPSS 13.0 statistical software package (Chicago, IL, USA). All P values <0.05 were considered to be statistically significant. The unpaired t-test, or t'-test according to the homogeneity test for variance, was used to compare measurement data and the chi-square or Fisher's exact test was used to compare enumeration data. Postoperative AF-free survival analysis was performed by the Kaplan-Meier method with a log-rank test for group comparisons. Pre-and peri-operative independent variables were assigned and the incidence of postoperative AF was calculated, then the chi-square or Fisher's exact test was performed to assess statistically significant variables, and those with P<0.05 were entered into the logistic regression analysis.
Results
Study Population
From March 2007 to March 2009, a total of 144 consecutive patients who met the inclusion criteria were randomly divided into a statin group (n=72) and a control group (n=72). Four patients were excluded (postoperative IABP requirement in 2 patients and postoperative acute renal failure requiring dialysis in 2 patients), so finally 140 patients (71 patients in the statin group, and 69 patients in the control group) were followed in this study. No cases of ventricular fibrillation, re-operation for bleeding, gastrointestinal bleeding, liver injury, or death occurred among the followed patients. Stroke and acute MI occurred in 2 patients in the control group on the 3rd and 5th day after operation, respectively. The incidence of major adverse cardiac and cerebrovascular events was similar in both groups. Demographic, clinical, and peri-operative variables were similar in both the statin and control groups, as shown in Tables 1 and 2 .
Postoperative AF As shown in Table 3 , postoperative AF occurred in 33 patients, with a prevalence of 24%. The average age of patients suffering from postoperative AF was 68.8±8.1 years, which was significantly higher than that of patients without postoperative AF, with an average age of 64.5±6.7 years (P=0.0026). The incidence of postoperative AF in the statin group was significantly lower than that in the control group (14% vs 34%, P=0.009), and the incidence of postoperative symptomatic AF in the statin group was significantly lower than that in the control group (8% vs 26%, P=0.007). As shown in Figure 1 , Kaplan-Meier curves confirmed a significantly better postoperative AF-free survival in the statin group ( χ2 =7.669, P=0.006). Intravenous infusion of amiodarone restored normal sinus rhythm in all patients suffering from postoperative AF. Until discharge from hospital, no patient in either group had recurrence of AF after cessation of the first episode. Cardioversion was not performed for postoperative AF in this study. The duration of postoperative AF in the statin group was significantly less than that in the control group (3.6±0.4 h vs 5.7±0.5 h, P<0.0001). The highest ventricular rate during postoperative AF in the statin group was 115± 9 beats/min, which was lower than that in the control group (141±16 beats/min) (P<0.0001). Postoperative time of AF occurrence in the statin group was 3.3±1.0 days, similar to that in the control group. Figure 2 , CRP levels increased sharply after surgery, reached a peak within 3 days, and then showed a slow decline. Baseline CRP levels (preoperative CRP levels) were not different between the 2 groups (3.6±1.5 mg/L in the statin group vs 4.1±1.7 mg/L in the control group, P=0.0669). However, the mean peak CRP level following OPCABG in the statin group was significantly lower than that in the control group (126.5±22.3 mg/L vs 145.2±31.6 mg/L, P< 0.0001). Patients with postoperative AF had higher peak CRP levels (165.7±29.4 mg/L in patients with AF vs 105.3± 18.7 mg/L in patients without AF, P<0.0001).
CRP Levels As shown in
Logistic Regression Analysis
Pre-and peri-operative independent variables were assigned and the incidence of postoperative AF was calculated, after which the chi-square or Fisher's exact test was performed. Pre-and peri-operative variables included older age (>65 years), sex, diabetes, hypertension, hypercholesterolemia, recent smoking (within 4 weeks of surgery), recent MI (evidence of MI in the last 30 days before surgery), chronic obstructive pulmonary disease, previous cerebral attack, previous percutaneous coronary intervention, preoperative congenital heart failure (NYHA class III or IV), left ventricular ejection fraction >0.5, left atrial diameter >45 mm, left ventricular diameter >55 mm, left main disease, multivessel coronary artery disease, proximal and middle lesions of the right coronary artery, preoperative administration of oral atorvastatin, β-blockers, calcium antagonists, digoxin and angiotensin-converting enzyme inhibitors, preoperative use of MgSO4, distal anastomoses, postoperative CRP level above the median value, postoperative magnesium <2 mg/dl, postoperative potassium <3.5 mmol/L, postoperative body temperature >38°C, and postoperative hypoxemia. 14 Statistically significant variables included older age, diabetes, hypertension, preoperative congenital heart failure, left atrial diameter >45 mm, proximal and middle lesions of right coronary artery, preoperative administration of oral atorvastatin, preoperative administration of oral β-blockers, preoperative use of MgSO4 and postoperative CRP level above the median value. Statistically significant variables were entered into the logistic regression analysis (occurrence or non-occurrence of postoperative AF as an independent variable, statistically significant variables as dependent factors), and independent risk factors for postoperative AF were obtained. Logistic regression analysis showed that independent risk factors for postoperative AF were older age (odds ratio (OR)=4.927, 95% confidence interval (CI) 1.548-15.684, P=0.007), postoperative CRP level above the median value (OR=2.011, 95%CI 1.235-7.628, P=0.013), proximal and middle lesions of the right coronary artery (OR=1.826, 95%CI 1.167-5.836, P=0.023), and preoperative administration of oral atorvastatin (OR= 0.219, 95%CI 0.076-0.633, P=0.005).
Discussion
In this study, AF following OPCABG occurred in 33 patients, with an incidence of 24%, which is than the 30-45% reported in other studies [1] [2] [3] [4] and mainly related to all selected patients undergoing OPCABG in this study. Our results showed that patients undergoing preoperative administration of oral atorvastatin had a lower incidence of postoperative AF vs preoperative administration of oral placebo (14% vs 34%, P=0.009), the Kaplan-Meier curves displayed a significantly better postoperative AF-free survival in the statin group vs the control group ( χ2 =7.669, P=0.006), and logistic regression analysis confirmed preoperative administration of oral atorvastatin as an independent factor associated with a significant reduction in postoperative AF (OR= 0.219, P=0.005). So, preoperative administration of oral atorvastatin decreased the risk of AF following OPCABG. The incidence of postoperative symptomatic AF in the statin group was significantly lower than that in the control group (8% vs 26%, P=0.007) and the highest ventricular rate in the statin group was significantly lower than that in the control group (115±9 beats/min vs 143±16 beats/min, P<0.001), which meant atorvastatin improved the precordial discomfort caused by AF. The fact that the duration of postoperative AF in the statin group was significantly shorter than that in the control group (3.6±0.4 h vs 5.7±0.5 h, P<0.0001) could be mainly related to a combination of postoperative administration of amiodarone and preoperative administration of atorvastatin.
Previous studies have confirmed that the inflammatory response plays an important role in the development of AF following CABG. 5, 6 Statins, independent of their cholesterol lowering property, are reported to reduce the risk of AF through their pleiotropic effects, such as their antiinflammatory and antioxidant properties, modification of extracellular matrix remodeling and indirect antiarrhythmic effects by autonomic modulation or direct antiarrhythmic effects through stabilization of transmembrane ion channel properties. [5] [6] [7] In the clinical setting the CRP level can be used as a marker of systemic inflammation. 3, 15, 16 In this study, the postoperative mean peak CRP level was higher in patients who developed postoperative AF (165.7±29.4 mg/L vs 105.3±18.7 mg/L in patients without AF, P<0.0001), and logistic regression analysis showed that a postoperative CRP level above the median value was associated with an increased risk of postoperative AF (OR=2.011, P=0.013). This study further confirmed the importance of inflammation in the development of AF following OPCABG. Preoperative CRP levels (baseline CRP levels) did not different between the 2 groups, but the postoperative peak CRP level in the statin group was significantly lower than that in the control group, which suggested that preoperative administration of oral atorvastatin reduced the inflammatory reaction to surgical trauma. This study showed that atorvastatin may reduce the risk of AF following OPCABG through a reduction in inflammation.
Previous studies have reported independent risk factors for AF following CABG as follows: older age, preoperative cardiac function, left atrial size, aortic cross-clamping time, etc. 2, 4, 13, 17 In this study, besides preoperative atorvastatin therapy and a postoperative CRP level above the median value, age over 65 and proximal and middle lesions of the right coronary artery were independent factors for AF following OPCABG. Also, the average age of the 33 patients with postoperative AF in the present study was 68.8±8.1 years and significantly higher than that of patients without postoperative AF, whose average age was 64.5±6.7 years (P=0.0026), and logistic regression analysis showed that the risk of postoperative AF in older patients (age over 65) was 4.927-fold higher than the risk of postoperative AF in patients aged under 65. This demonstrated that older age was closely related to the development of postoperative AF, mainly because of degenerative changes in the sinoatrial node, which means maintenance of sinus rhythm becomes more and more difficult. Also, age-related changes in cardiac structure (such as atrial expansion, myocardial fibrosis etc) are increasingly common in the older patients, resulting in multiple re-entrant wavelets and consequently initiation and perpetuation of AF. We found that proximal and middle lesions of the right coronary artery increased the risk of postoperative AF. The blood supply of the sino-atrial and atrioventricular nodes comes from these parts of the right coronary artery, so their function, as well as their conduction properties, will be affected by proximal and middle stenosis, resulting in AF following OPCABG. Because of the dominant right coronary artery in Chinese, 18 proximal and middle lesions would play an important role in development of postoperative AF.
In conclusion, this study demonstrated that preoperative administration of oral atorvastatin 20 mg/day, initiated 1 week before scheduled OPCABG and continued in the postoperative period, significantly decreases the development of AF.
